Datapoint: FDA Approves Biogen’s Lucentis Biosimilar

The FDA on Monday approved Biogen and Samsung Bioepis’ Byooviz, a biosimilar to Roche’s blockbuster eye drug Lucentis. The approval marks Samsung Bioepis’ fifth biosimilar win. For the treatment of age-related macular degeneration, Lucentis holds covered or better status for 49% of all insured lives under the pharmacy benefit. It is not covered for 30.6% of lives.

SOURCE: MMIT Analytics, as of 9/22/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 12

Datapoint: Pfizer Inks Biohaven Deal

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 11

Datapoint: Sentara to Open Community Care Centers, Launch New Model

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 10

Datapoint: Centene to Sell Two Specialty Pharma Businesses

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today